# One-year Success Rate of Selective Laser Trabeculoplasty in Pseudoexfoliative Glaucoma: A Prospective Study

## TL;DR

Selective laser trabeculoplasty effectively lowers eye pressure in pseudoexfoliative glaucoma patients for one year with minimal side effects.

## Contribution

Reports the 1-year success rate of SLT in PEXG patients, showing its effectiveness as a primary or complementary treatment.

## Key findings

- SLT reduced intraocular pressure by 31% on average over one year in PEXG patients.
- The 1-year success rate was 85%, with minimal adverse effects like mild inflammation.
- The number of glaucoma medications remained unchanged after the procedure.

## Abstract

To evaluate the 1-year effectiveness of selective laser trabeculoplasty (SLT) in patients with pseudoexfoliative glaucoma (PEXG).

This prospective, single-arm, non-randomized interventional study involved 40 eyes from 40 patients with PEXG with no history of glaucoma surgery and laser trabeculoplasty. All participants underwent a single session of 360º SLT. Follow-up visits were conducted at 2 hours, 1 day, 1 week, and at 1, 2, 3, 4, 5, 6, and 12 months after the procedure. The intraocular pressure (IOP), the number of anti-glaucoma medications (NOM), and the 1-year success rate were investigated as primary outcome measures; while the incidence of adverse effects was considered the secondary outcome. Treatment success was defined as a
≥
20% decrease in IOP compared to baseline.

The baseline IOP was 22.19
±
2.08 mmHg, and the mean NOM was 3.12
±
0.55 before the SLT procedure. The mean IOP was significantly lower at all follow-up visits than at baseline, whereas the mean NOM remained unchanged throughout the follow-up period. The mean IOP values at 1, 3, 6, and 12 months after SLT were 18.02, 16.92, 16.47, and 15.31 mmHg, respectively. The overall 1-year success rate was 85%, with an average IOP reduction of 31.0% relative to baseline. The most common adverse event following SLT was mild anterior chamber inflammation, which occurred in 32.5% of eyes.

The SLT procedure could significantly reduce IOP in patients with PEXG with minimal adverse effects. The 1-year outcomes were favorable, suggesting that SLT may serve as an effective primary or complementary treatment for PEXG.